Moderna (NASDAQ: MRNA) stock was down by 1.68% at close Thursday. Those Investors who focused on the biopharmaceutical stocks were not excited about this news that published by the company on Wednesday.
The company expects it will raise global 2022 capacity to up to 3 billion doses of its COVID-19 vaccine through its owned and partnered manufacturing facilities, depending on the mix of product between primary series of vaccination and variant boosters. The company also raised its 2021 manufacturing supply forecast to between 800 million to 1 billion doses.
The company believes that there is an expected significant need for booster vaccinations in 2022 and beyond, so, this investment in increased supply is necessary. The company also said it's working on the next generation COVID-19 vaccine, which will extend refrigerated shelf life even further.
More COVID-19 vaccine supply which means more income for the company, but there are still huge loss numbers in the company's financial results report. In 2020, the company had a net loss of $747 million and $272 million were a net loss of the company for the fourth quarter. These factual figures will limit its stock price to rise dramatically.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.